Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2020

View Archived Issues

Brown fat activity without fat browning

FDA lifts hold and clears IND application for IMS-001

Agonists selectively wake up melatonin receptor subtypes

IND application for AG-946 cleared by FDA

Enhancing TREM2's protective function on microglia as a novel approach for Alzheimer's disease

Ciclesonide shows antiviral activity against SARS-CoV-2

First patients enrolled in RECOVERY study evaluating potential COVID-19 treatments

Vaccitech presents initial data from phase IIa ADVANCE study of VTP-800

miR-423-5p and miR-128-3p in serum exosome as biomarkers for testicular injury

Novel lipid biomarkers for ETH-induced hepatic steatosis

Elevated AXIN1 expression as predictor of PTSD development

TNFSF14 is a therapeutic target in eosinophilic esophagitis

Biomarkers predict renal recovery from acute kidney injury requiring dialysis

Nanocells deliver cytotoxin, activate immune system

Roche and Genentech patent TEAD inhibitors

Novartis divulges new compounds for herpesvirus infection

H. Lee Moffitt Cancer Center and Research Institute presents BRD4-JAK2 inhibitors

Otsuka Pharmaceutical identifies AhR antagonists

New AMPK activators presented by Skylark Bioscience

Ascletis publishes data from clinical study of danoprevir for COVID-19

Novartis' Beovu approved in Japan for neovascular age-related macular degeneration

Japanese approval of Tepmetko for advanced NSCLC with METex14 skipping alterations

Phase I results with losmapimod for FSHD show target engagement in muscle

Antolimab begins new trials, shows promise for mast cell gastrointestinal disease

BeiGene studies BGB-11417 in phase I for mature B-cell malignancies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...